Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antibiotic showdown: which drug better protects mothers and babies after water breaks early?

NCT ID NCT07394725

Disease control Sponsor: District Headquarters Teaching Hospital Sahiwal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two antibiotics, azithromycin and erythromycin, in 250 pregnant women whose water broke too early (between 28 and 34 weeks). The goal was to see which drug better prevents infection in the mother and improves newborn health. Participants took one of the two antibiotics for seven days, and the researchers tracked infection signs and baby outcomes at birth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

250 people

The number who actually took part.

Started

Apr 2024

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women * Aged 18 to 40 years * Singleton pregnancy with PPROM and * 28 weeks 0 days to 33 weeks 6 days of gestation. Exclusion Criteria: * Pregnancy was before 28 weeks * Possible fetal defects * Signs of active labor * Major vaginal bleeding * Signs of chorioamnionitis on arrival * Placenta previa or placental abruption * Allergic to macrolide antibiotics or received antibiotic treatment less than five days earlier were all excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-term premature rupture of membranes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

preterm premature rupture of the membranes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-term premature rupture of membranes

Contacts and locations

Locations

  • Sahiwal Teaching Hospital , Sahiwal

    Sāhīwāl, Punjab Province, 57000, Pakistan